Quidel Corp (QDEL) Tops Q4 EPS by 18c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Quidel Reports Fourth Quarter and Full Year 2019 Financial Results
February 12, 2020 4:10 PM ESTSAN DIEGO--(BUSINESS WIRE)-- Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and the year ended December 31, 2019.
Fourth Quarter 2019 Highlights
Total revenue increased 15% to $152.2 million, compared with $132.6 million in the fourth quarter of 2018. Cardiac Immunoassay revenue increased 5% to $65.8 million. Molecular Diagnostic Solutions revenue was $7.1 million, 21% growth from the fourth quarter of 2018. Influenza revenue increased 44% to $50.3 million, compared with $34.9 million in the fourth quarter of... More


